[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,043
  • Shares Outstanding, K 31,375
  • Annual Sales, $ 90 K
  • Annual Income, $ -33,890 K
  • EBIT $ -36 M
  • EBITDA $ -35 M
  • 60-Month Beta -0.11
  • Price/Sales 456.68
  • Price/Cash Flow N/A
  • Price/Book 5.22

Options Overview Details

View History
  • Implied Volatility 307.90% (-10.90%)
  • Historical Volatility 83.07%
  • IV Percentile 57%
  • IV Rank 24.84%
  • IV High 1,130.39% on 12/03/25
  • IV Low 36.03% on 03/17/26
  • Expected Move (DTE 3) 0.0085 (0.64%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 62
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 3,347
  • Open Int (30-Day) 3,133
  • Expected Range 1.3115 to 1.3285

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 1
  • High Estimate $-0.25
  • Low Estimate $-0.25
  • Prior Year $-0.22
  • Growth Rate Est. (year over year) -13.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0600 +24.53%
on 04/13/26
1.5294 -13.69%
on 04/21/26
+0.2400 (+22.22%)
since 04/10/26
3-Month
0.9520 +38.66%
on 03/31/26
1.5294 -13.69%
on 04/21/26
+0.2100 (+18.92%)
since 02/12/26
52-Week
0.9520 +38.66%
on 03/31/26
1.9454 -32.15%
on 06/10/25
-0.2300 (-14.84%)
since 05/12/25

Most Recent Stories

More News
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

– ATNM-400 in NSCLC: New data demonstrates ATNM-400's potential in KRAS-mutated models supporting its development as a mutation-agnostic therapy in settings where resistance to EGFR- and KRAS-targeted...

ATNM : 1.3050 (-2.61%)
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

NEW YORK , April 22, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced...

ATNM : 1.3050 (-2.61%)
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

NEW YORK , April 22, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted...

ATNM : 1.3050 (-2.61%)
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

NEW YORK , April 6, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced...

ATNM : 1.3050 (-2.61%)
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

ATNM : 1.3050 (-2.61%)
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

-       ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the...

ATNM : 1.3050 (-2.61%)
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical...

ATNM : 1.3050 (-2.61%)
The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 17, 2025) - Investorideas.com, a go-to investing platform covering biotech and pharma stocks issues a snapshot looking at the...

ATNM : 1.3050 (-2.61%)
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications

-  New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab

ATNM : 1.3050 (-2.61%)
Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies,...

ATNM : 1.3050 (-2.61%)

Business Summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended...

See More

Key Turning Points

3rd Resistance Point 1.4733
2nd Resistance Point 1.4267
1st Resistance Point 1.3833
Last Price 1.3050
1st Support Level 1.2933
2nd Support Level 1.2467
3rd Support Level 1.2033

See More

52-Week High 1.9454
Fibonacci 61.8% 1.5659
Fibonacci 50% 1.4487
Fibonacci 38.2% 1.3315
Last Price 1.3050
52-Week Low 0.9520

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.